ID   KS6A3_HUMAN             Reviewed;         740 AA.
AC   P51812; B2R9V4; Q4VAP3; Q59H26; Q5JPK8; Q7Z3Z7;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   12-OCT-2022, entry version 219.
DE   RecName: Full=Ribosomal protein S6 kinase alpha-3;
DE            Short=S6K-alpha-3;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:17213202};
DE   AltName: Full=90 kDa ribosomal protein S6 kinase 3;
DE            Short=p90-RSK 3;
DE            Short=p90RSK3;
DE   AltName: Full=Insulin-stimulated protein kinase 1;
DE            Short=ISPK-1;
DE   AltName: Full=MAP kinase-activated protein kinase 1b;
DE            Short=MAPK-activated protein kinase 1b;
DE            Short=MAPKAP kinase 1b;
DE            Short=MAPKAPK-1b;
DE   AltName: Full=Ribosomal S6 kinase 2;
DE            Short=RSK-2;
DE   AltName: Full=pp90RSK2;
GN   Name=RPS6KA3; Synonyms=ISPK1, MAPKAPK1B, RSK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta, and T-cell;
RX   PubMed=7813820; DOI=10.2337/diab.44.1.90;
RA   Bjoerbaek C., Vik T.A., Echwald S.M., Webb G.C., Wang J.P., Yang P.-Y.,
RA   Vestergaard H., Richmond K., Hansen T., Erikson R.L., Miklos G.L.G.,
RA   Cohen P.T.W., Pedersen O.;
RT   "Cloning of a human insulin-stimulated protein kinase (ISPK-1) gene and
RT   analysis of coding regions and mRNA levels of the ISPK-1 and the protein
RT   phosphatase-1 genes in muscle from NIDDM patients.";
RL   Diabetes 44:90-97(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2-582.
RC   TISSUE=Skeletal muscle;
RX   PubMed=8141249; DOI=10.1152/ajpcell.1994.266.2.c351;
RA   Moller D.E., Xia C.-H., Tang W., Zhu A.X., Jakubowski M.;
RT   "Human rsk isoforms: cloning and characterization of tissue-specific
RT   expression.";
RL   Am. J. Physiol. 266:C351-C359(1994).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 15-735.
RX   PubMed=12777533; DOI=10.1093/molbev/msg134;
RA   Kitano T., Schwarz C., Nickel B., Paeaebo S.;
RT   "Gene diversity patterns at 10 X-chromosomal loci in humans and
RT   chimpanzees.";
RL   Mol. Biol. Evol. 20:1281-1289(2003).
RN   [8]
RP   FUNCTION IN PHOSPHORYLATION OF GSK3B.
RX   PubMed=8250835; DOI=10.1042/bj2960015;
RA   Sutherland C., Leighton I.A., Cohen P.;
RT   "Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new
RT   kinase connections in insulin and growth-factor signalling.";
RL   Biochem. J. 296:15-19(1993).
RN   [9]
RP   FUNCTION IN PHOSPHORYLATION OF CREB1.
RX   PubMed=9770464; DOI=10.1073/pnas.95.21.12202;
RA   De Cesare D., Jacquot S., Hanauer A., Sassone-Corsi P.;
RT   "Rsk-2 activity is necessary for epidermal growth factor-induced
RT   phosphorylation of CREB protein and transcription of c-fos gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:12202-12207(1998).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF HISTONE H3.
RX   PubMed=10436156; DOI=10.1126/science.285.5429.886;
RA   Sassone-Corsi P., Mizzen C.A., Cheung P., Crosio C., Monaco L., Jacquot S.,
RA   Hanauer A., Allis C.D.;
RT   "Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation
RT   of histone H3.";
RL   Science 285:886-891(1999).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF DAPK1.
RX   PubMed=16213824; DOI=10.1016/j.cub.2005.08.050;
RA   Anjum R., Roux P.P., Ballif B.A., Gygi S.P., Blenis J.;
RT   "The tumor suppressor DAP kinase is a target of RSK-mediated survival
RT   signaling.";
RL   Curr. Biol. 15:1762-1767(2005).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF NR4A1/NUR77.
RX   PubMed=16223362; DOI=10.1042/bj20050967;
RA   Wingate A.D., Campbell D.G., Peggie M., Arthur J.S.;
RT   "Nur77 is phosphorylated in cells by RSK in response to mitogenic
RT   stimulation.";
RL   Biochem. J. 393:715-724(2006).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-715, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [14]
RP   CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, INTERACTION WITH NFATC4,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=17213202; DOI=10.1074/jbc.m611322200;
RA   Cho Y.-Y., Yao K., Bode A.M., Bergen H.R. III, Madden B.J., Oh S.-M.,
RA   Ermakova S., Kang B.S., Choi H.S., Shim J.-H., Dong Z.;
RT   "RSK2 mediates muscle cell differentiation through regulation of NFAT3.";
RL   J. Biol. Chem. 282:8380-8392(2007).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF RPS6.
RX   PubMed=17360704; DOI=10.1074/jbc.m700906200;
RA   Roux P.P., Shahbazian D., Vu H., Holz M.K., Cohen M.S., Taunton J.,
RA   Sonenberg N., Blenis J.;
RT   "RAS/ERK signaling promotes site-specific ribosomal protein S6
RT   phosphorylation via RSK and stimulates cap-dependent translation.";
RL   J. Biol. Chem. 282:14056-14064(2007).
RN   [16]
RP   FUNCTION IN MTOR SIGNALING.
RX   PubMed=18722121; DOI=10.1016/j.cub.2008.07.078;
RA   Carriere A., Cargnello M., Julien L.A., Gao H., Bonneil E., Thibault P.,
RA   Roux P.P.;
RT   "Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-
RT   mediated raptor phosphorylation.";
RL   Curr. Biol. 18:1269-1277(2008).
RN   [17]
RP   REVIEW ON FUNCTION, AND REVIEW ON ACTIVITY REGULATION.
RX   PubMed=18508509; DOI=10.2741/3003;
RA   Carriere A., Ray H., Blenis J., Roux P.P.;
RT   "The RSK factors of activating the Ras/MAPK signaling cascade.";
RL   Front. Biosci. 13:4258-4275(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-365; SER-369; SER-375;
RP   SER-386; SER-415; SER-556 AND SER-715, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [19]
RP   REVIEW ON FUNCTION, AND REVIEW ON ACTIVITY REGULATION.
RX   PubMed=18813292; DOI=10.1038/nrm2509;
RA   Anjum R., Blenis J.;
RT   "The RSK family of kinases: emerging roles in cellular signalling.";
RL   Nat. Rev. Mol. Cell Biol. 9:747-758(2008).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-365; SER-369 AND SER-375, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-365; SER-369; SER-375;
RP   SER-386; SER-415 AND SER-715, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-415, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-715, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-365 AND SER-369, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-365; SER-369; SER-415 AND
RP   SER-715, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-369; SER-386; SER-415 AND
RP   SER-715, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [28]
RP   FUNCTION IN PHOSPHORYLATION OF EPHA2.
RX   PubMed=26158630; DOI=10.1038/ncomms8679;
RA   Zhou Y., Yamada N., Tanaka T., Hori T., Yokoyama S., Hayakawa Y., Yano S.,
RA   Fukuoka J., Koizumi K., Saiki I., Sakurai H.;
RT   "Crucial roles of RSK in cell motility by catalysing serine phosphorylation
RT   of EphA2.";
RL   Nat. Commun. 6:7679-7679(2015).
RN   [29]
RP   VARIANTS CLS VAL-75 AND ALA-227.
RX   PubMed=8955270; DOI=10.1038/384567a0;
RA   Trivier E., de Cesare D., Jacquot S., Pannetier S., Zackai E., Young I.,
RA   Mandel J.-L., Sassone-Corsi P., Hanauer A.;
RT   "Mutations in the kinase Rsk-2 associated with Coffin-Lowry syndrome.";
RL   Nature 384:567-570(1996).
RN   [30]
RP   VARIANTS CLS PHE-82; GLN-127; TYR-154; VAL-225 AND ASP-431, AND VARIANT
RP   SER-38.
RX   PubMed=9837815; DOI=10.1086/302153;
RA   Jacquot S., Merienne K., de Cesare D., Pannetier S., Mandel J.-L.,
RA   Sassone-Corsi P., Hanauer A.;
RT   "Mutation analysis of the RSK2 gene in Coffin-Lowry patients: extensive
RT   allelic heterogeneity and a high rate of De novo mutations.";
RL   Am. J. Hum. Genet. 63:1631-1640(1998).
RN   [31]
RP   VARIANTS CLS TRP-114 AND GLN-729.
RX   PubMed=10094187; DOI=10.1038/sj.ejhg.5200231;
RA   Abidi F., Jacquot S., Lassiter C., Trivier E., Hanauer A., Schwartz C.E.;
RT   "Novel mutations in Rsk-2, the gene for Coffin-Lowry syndrome (CLS).";
RL   Eur. J. Hum. Genet. 7:20-26(1999).
RN   [32]
RP   VARIANT CLS LYS-189.
RX   PubMed=10528858; DOI=10.1136/jmg.36.10.775;
RA   Manouvrier-Hanu S., Amiel J., Jacquot S., Merienne K., Moerman A.,
RA   Coeslier A., Labarriere F., Vallee L., Croquette M.F., Hanauer A.;
RT   "Unreported RSK2 missense mutation in two male sibs with an unusually mild
RT   form of Coffin-Lowry syndrome.";
RL   J. Med. Genet. 36:775-778(1999).
RN   [33]
RP   VARIANT XLID19 TRP-383, AND CHARACTERIZATION OF VARIANT XLID19 TRP-383.
RX   PubMed=10319851; DOI=10.1038/8719;
RA   Merienne K., Jacquot S., Pannetier S., Zeniou M., Bankier A., Gecz J.,
RA   Mandel J.L., Mulley J., Sassone-Corsi P., Hanauer A.;
RT   "A missense mutation in RPS6KA3 (RSK2) responsible for non-specific mental
RT   retardation.";
RL   Nat. Genet. 22:13-14(1999).
RN   [34]
RP   VARIANT CLS SER-268.
RX   PubMed=14986828; DOI=10.1046/j.1399-0004.2003.00166.x;
RA   Martinez-Garay I., Ballesta M.J., Oltra S., Orellana C., Palomeque A.,
RA   Molto M.D., Prieto F., Martinez F.;
RT   "Intronic L1 insertion and F268S, novel mutations in RPS6KA3 (RSK2) causing
RT   Coffin-Lowry syndrome.";
RL   Clin. Genet. 64:491-496(2003).
RN   [35]
RP   VARIANT CLS ILE-477 DEL.
RX   PubMed=15214012; DOI=10.1002/ajmg.a.30056;
RA   Facher J.J., Regier E.J., Jacobs G.H., Siwik E., Delaunoy J.P., Robin N.H.;
RT   "Cardiomyopathy in Coffin-Lowry syndrome.";
RL   Am. J. Med. Genet. A 128:176-178(2004).
RN   [36]
RP   VARIANTS XLID19 SER-115; GLY-152 DEL AND ASP-202 DEL.
RX   PubMed=17100996; DOI=10.1111/j.1399-0004.2006.00723.x;
RA   Field M., Tarpey P., Boyle J., Edkins S., Goodship J., Luo Y., Moon J.,
RA   Teague J., Stratton M.R., Futreal P.A., Wooster R., Raymond F.L.,
RA   Turner G.;
RT   "Mutations in the RSK2(RPS6KA3) gene cause Coffin-Lowry syndrome and
RT   nonsyndromic X-linked mental retardation.";
RL   Clin. Genet. 70:509-515(2006).
RN   [37]
RP   VARIANT [LARGE SCALE ANALYSIS] VAL-416.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [38]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-38; CYS-483; PHE-608 AND CYS-723.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that acts downstream of ERK
CC       (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and
CC       stress-induced activation of the transcription factors CREB1, ETV1/ER81
CC       and NR4A1/NUR77, regulates translation through RPS6 and EIF4B
CC       phosphorylation, and mediates cellular proliferation, survival, and
CC       differentiation by modulating mTOR signaling and repressing pro-
CC       apoptotic function of BAD and DAPK1 (PubMed:9770464, PubMed:16223362,
CC       PubMed:17360704, PubMed:16213824). In fibroblast, is required for EGF-
CC       stimulated phosphorylation of CREB1 and histone H3 at 'Ser-10', which
CC       results in the subsequent transcriptional activation of several
CC       immediate-early genes (PubMed:9770464, PubMed:10436156). In response to
CC       mitogenic stimulation (EGF and PMA), phosphorylates and activates
CC       NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP
CC       (PubMed:16223362). Upon insulin-derived signal, acts indirectly on the
CC       transcription regulation of several genes by phosphorylating GSK3B at
CC       'Ser-9' and inhibiting its activity (PubMed:8250835). Phosphorylates
CC       RPS6 in response to serum or EGF via an mTOR-independent mechanism and
CC       promotes translation initiation by facilitating assembly of the
CC       preinitiation complex (PubMed:17360704). In response to insulin,
CC       phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and
CC       stimulating cap-dependent translation (PubMed:18508509,
CC       PubMed:18813292). Is involved in the mTOR nutrient-sensing pathway by
CC       directly phosphorylating TSC2 at 'Ser-1798', which potently inhibits
CC       TSC2 ability to suppress mTOR signaling, and mediates phosphorylation
CC       of RPTOR, which regulates mTORC1 activity and may promote rapamycin-
CC       sensitive signaling independently of the PI3K/AKT pathway
CC       (PubMed:18722121). Mediates cell survival by phosphorylating the pro-
CC       apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic
CC       function (PubMed:16213824). Promotes the survival of hepatic stellate
CC       cells by phosphorylating CEBPB in response to the hepatotoxin carbon
CC       tetrachloride (CCl4) (PubMed:18508509, PubMed:18813292). Is involved in
CC       cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B,
CC       which promotes CDKN1B association with 14-3-3 proteins and prevents its
CC       translocation to the nucleus and inhibition of G1 progression (By
CC       similarity). In LPS-stimulated dendritic cells, is involved in TLR4-
CC       induced macropinocytosis, and in myeloma cells, acts as effector of
CC       FGFR3-mediated transformation signaling, after direct phosphorylation
CC       at Tyr-529 by FGFR3 (By similarity). Negatively regulates EGF-induced
CC       MAPK1/3 phosphorylation via phosphorylation of SOS1 (By similarity).
CC       Phosphorylates SOS1 at 'Ser-1134' and 'Ser-1161' that create YWHAB and
CC       YWHAE binding sites and which contribute to the negative regulation of
CC       MAPK1/3 phosphorylation (By similarity). Phosphorylates EPHA2 at 'Ser-
CC       897', the RPS6KA-EPHA2 signaling pathway controls cell migration
CC       (PubMed:26158630). Acts as a regulator of osteoblast differentiation by
CC       mediating phosphorylation of ATF4, thereby promoting ATF4
CC       transactivation activity (By similarity).
CC       {ECO:0000250|UniProtKB:P18654, ECO:0000269|PubMed:10436156,
CC       ECO:0000269|PubMed:16213824, ECO:0000269|PubMed:16223362,
CC       ECO:0000269|PubMed:17360704, ECO:0000269|PubMed:18722121,
CC       ECO:0000269|PubMed:26158630, ECO:0000269|PubMed:8250835,
CC       ECO:0000269|PubMed:9770464, ECO:0000303|PubMed:18508509,
CC       ECO:0000303|PubMed:18813292}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:17213202};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ACTIVITY REGULATION: Upon extracellular signal or mitogen stimulation,
CC       phosphorylated at Thr-577 in the C-terminal kinase domain (CTKD) by
CC       MAPK1/ERK2 and MAPK3/ERK1. The activated CTKD then autophosphorylates
CC       Ser-386, allowing binding of PDPK1, which in turn phosphorylates Ser-
CC       227 in the N-terminal kinase domain (NTDK) leading to the full
CC       activation of the protein and subsequent phosphorylation of the
CC       substrates by the NTKD.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=3.56 uM for NFATC4 {ECO:0000269|PubMed:17213202};
CC         Vmax=11.5 umol/min/ug enzyme toward ATP
CC         {ECO:0000269|PubMed:17213202};
CC   -!- SUBUNIT: Forms a complex with either MAPK1/ERK2 or MAPK3/ERK1 in
CC       quiescent cells. Transiently dissociates following mitogenic
CC       stimulation (By similarity). Interacts with NFATC4, ETV1/ER81 and
CC       FGFR1. {ECO:0000250, ECO:0000269|PubMed:17213202}.
CC   -!- INTERACTION:
CC       P51812; P46379-2: BAG6; NbExp=3; IntAct=EBI-1046616, EBI-10988864;
CC       P51812; P67870: CSNK2B; NbExp=4; IntAct=EBI-1046616, EBI-348169;
CC       P51812; P09471: GNAO1; NbExp=3; IntAct=EBI-1046616, EBI-715087;
CC       P51812; P08238: HSP90AB1; NbExp=3; IntAct=EBI-1046616, EBI-352572;
CC       P51812; O14901: KLF11; NbExp=3; IntAct=EBI-1046616, EBI-948266;
CC       P51812; P28482: MAPK1; NbExp=7; IntAct=EBI-1046616, EBI-959949;
CC       P51812; Q9HC98-4: NEK6; NbExp=3; IntAct=EBI-1046616, EBI-11750983;
CC       P51812; Q6P4D5-2: PABIR3; NbExp=3; IntAct=EBI-1046616, EBI-9091052;
CC       P51812; P27986-2: PIK3R1; NbExp=3; IntAct=EBI-1046616, EBI-9090282;
CC       P51812; Q7Z698: SPRED2; NbExp=4; IntAct=EBI-1046616, EBI-7082156;
CC       P51812; A1JU68: yopM; Xeno; NbExp=2; IntAct=EBI-1046616, EBI-26365850;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:17213202}. Cytoplasm
CC       {ECO:0000269|PubMed:17213202}.
CC   -!- TISSUE SPECIFICITY: Expressed in many tissues, highest levels in
CC       skeletal muscle.
CC   -!- PTM: Activated by phosphorylation at Ser-227 by PDPK1.
CC       Autophosphorylated on Ser-386, as part of the activation process. May
CC       be phosphorylated at Thr-365 and Ser-369 by MAPK1/ERK2 and MAPK3/ERK1.
CC       Can also be activated via phosphorylation at Ser-386 by MAPKAPK2.
CC   -!- PTM: N-terminal myristoylation results in an activated kinase in the
CC       absence of added growth factors.
CC   -!- DISEASE: Coffin-Lowry syndrome (CLS) [MIM:303600]: An X-linked disorder
CC       characterized by intellectual disability associated with facial and
CC       digital dysmorphisms, progressive skeletal malformations, growth
CC       retardation, hearing deficit and paroxysmal movement disorders.
CC       {ECO:0000269|PubMed:10094187, ECO:0000269|PubMed:10528858,
CC       ECO:0000269|PubMed:14986828, ECO:0000269|PubMed:15214012,
CC       ECO:0000269|PubMed:8955270, ECO:0000269|PubMed:9837815}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Intellectual developmental disorder, X-linked 19 (XLID19)
CC       [MIM:300844]: A disorder characterized by significantly below average
CC       general intellectual functioning associated with impairments in
CC       adaptive behavior and manifested during the developmental period.
CC       {ECO:0000269|PubMed:10319851, ECO:0000269|PubMed:17100996}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. S6 kinase subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92170.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U08316; AAA81952.1; -; mRNA.
DR   EMBL; AK313932; BAG36651.1; -; mRNA.
DR   EMBL; AB208933; BAD92170.1; ALT_INIT; mRNA.
DR   EMBL; AL732366; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL807772; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC096301; AAH96301.1; -; mRNA.
DR   EMBL; BC096302; AAH96302.1; -; mRNA.
DR   EMBL; BC096303; AAH96303.1; -; mRNA.
DR   EMBL; L07599; AAC82495.1; -; mRNA.
DR   EMBL; AB102662; BAC81131.1; -; mRNA.
DR   CCDS; CCDS14197.1; -.
DR   PIR; I38556; I38556.
DR   RefSeq; NP_004577.1; NM_004586.2.
DR   PDB; 4D9T; X-ray; 2.40 A; A=399-740.
DR   PDB; 4D9U; X-ray; 2.40 A; A=399-740.
DR   PDB; 4JG6; X-ray; 2.60 A; A=399-740.
DR   PDB; 4JG7; X-ray; 3.00 A; A=399-740.
DR   PDB; 4JG8; X-ray; 3.10 A; A=399-740.
DR   PDB; 4NUS; X-ray; 2.39 A; A=39-359.
DR   PDB; 4NW5; X-ray; 1.94 A; A=39-359.
DR   PDB; 4NW6; X-ray; 1.74 A; A=39-359.
DR   PDB; 5D9K; X-ray; 2.55 A; A/B=39-366.
DR   PDB; 5D9L; X-ray; 2.15 A; A=39-359.
DR   PDB; 7OPO; X-ray; 2.75 A; A/C/E/G/I/K=39-351.
DR   PDBsum; 4D9T; -.
DR   PDBsum; 4D9U; -.
DR   PDBsum; 4JG6; -.
DR   PDBsum; 4JG7; -.
DR   PDBsum; 4JG8; -.
DR   PDBsum; 4NUS; -.
DR   PDBsum; 4NW5; -.
DR   PDBsum; 4NW6; -.
DR   PDBsum; 5D9K; -.
DR   PDBsum; 5D9L; -.
DR   PDBsum; 7OPO; -.
DR   AlphaFoldDB; P51812; -.
DR   SMR; P51812; -.
DR   BioGRID; 112111; 161.
DR   DIP; DIP-38247N; -.
DR   IntAct; P51812; 98.
DR   MINT; P51812; -.
DR   STRING; 9606.ENSP00000368884; -.
DR   BindingDB; P51812; -.
DR   ChEMBL; CHEMBL2345; -.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; P51812; -.
DR   GuidetoPHARMACOLOGY; 1528; -.
DR   GlyGen; P51812; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P51812; -.
DR   MetOSite; P51812; -.
DR   PhosphoSitePlus; P51812; -.
DR   BioMuta; RPS6KA3; -.
DR   DMDM; 1730070; -.
DR   EPD; P51812; -.
DR   jPOST; P51812; -.
DR   MassIVE; P51812; -.
DR   MaxQB; P51812; -.
DR   PaxDb; P51812; -.
DR   PeptideAtlas; P51812; -.
DR   PRIDE; P51812; -.
DR   ProteomicsDB; 56408; -.
DR   Antibodypedia; 1004; 611 antibodies from 35 providers.
DR   DNASU; 6197; -.
DR   Ensembl; ENST00000379565.9; ENSP00000368884.3; ENSG00000177189.14.
DR   GeneID; 6197; -.
DR   KEGG; hsa:6197; -.
DR   MANE-Select; ENST00000379565.9; ENSP00000368884.3; NM_004586.3; NP_004577.1.
DR   UCSC; uc004czu.4; human.
DR   CTD; 6197; -.
DR   DisGeNET; 6197; -.
DR   GeneCards; RPS6KA3; -.
DR   GeneReviews; RPS6KA3; -.
DR   HGNC; HGNC:10432; RPS6KA3.
DR   HPA; ENSG00000177189; Low tissue specificity.
DR   MalaCards; RPS6KA3; -.
DR   MIM; 300075; gene.
DR   MIM; 300844; phenotype.
DR   MIM; 303600; phenotype.
DR   neXtProt; NX_P51812; -.
DR   OpenTargets; ENSG00000177189; -.
DR   Orphanet; 192; Coffin-Lowry syndrome.
DR   Orphanet; 276630; Symptomatic form of Coffin-Lowry syndrome in female carriers.
DR   Orphanet; 777; X-linked non-syndromic intellectual disability.
DR   PharmGKB; PA34847; -.
DR   VEuPathDB; HostDB:ENSG00000177189; -.
DR   eggNOG; KOG0603; Eukaryota.
DR   GeneTree; ENSGT00940000159370; -.
DR   HOGENOM; CLU_000288_58_3_1; -.
DR   InParanoid; P51812; -.
DR   OMA; VINCCEA; -.
DR   OrthoDB; 1132245at2759; -.
DR   PhylomeDB; P51812; -.
DR   TreeFam; TF313438; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; P51812; -.
DR   Reactome; R-HSA-198753; ERK/MAPK targets.
DR   Reactome; R-HSA-199920; CREB phosphorylation.
DR   Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR   Reactome; R-HSA-437239; Recycling pathway of L1.
DR   Reactome; R-HSA-442742; CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling.
DR   Reactome; R-HSA-444257; RSK activation.
DR   Reactome; R-HSA-881907; Gastrin-CREB signalling pathway via PKC and MAPK.
DR   SignaLink; P51812; -.
DR   SIGNOR; P51812; -.
DR   BioGRID-ORCS; 6197; 22 hits in 738 CRISPR screens.
DR   ChiTaRS; RPS6KA3; human.
DR   GeneWiki; RPS6KA3; -.
DR   GenomeRNAi; 6197; -.
DR   Pharos; P51812; Tchem.
DR   PRO; PR:P51812; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; P51812; protein.
DR   Bgee; ENSG00000177189; Expressed in cartilage tissue and 202 other tissues.
DR   ExpressionAtlas; P51812; baseline and differential.
DR   Genevisible; P51812; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0045202; C:synapse; IEA:GOC.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0043027; F:cysteine-type endopeptidase inhibitor activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0004711; F:ribosomal protein S6 kinase activity; IBA:GO_Central.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0007417; P:central nervous system development; TAS:ProtInc.
DR   GO; GO:0007268; P:chemical synaptic transmission; TAS:Reactome.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; TAS:UniProtKB.
DR   GO; GO:0030307; P:positive regulation of cell growth; TAS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0043620; P:regulation of DNA-templated transcription in response to stress; TAS:UniProtKB.
DR   GO; GO:0043555; P:regulation of translation in response to stress; TAS:UniProtKB.
DR   GO; GO:0032496; P:response to lipopolysaccharide; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0001501; P:skeletal system development; TAS:ProtInc.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; ISS:UniProtKB.
DR   CDD; cd14176; STKc_RSK2_C; 1.
DR   CDD; cd05582; STKc_RSK_N; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR016239; Ribosomal_S6_kinase_II.
DR   InterPro; IPR041905; RPS6KA3_C.
DR   InterPro; IPR041906; RSK_N.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 2.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000606; Ribsml_S6_kin_2; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 2.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 2.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 2.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 2.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell cycle; Cytoplasm; Disease variant;
KW   Intellectual disability; Kinase; Magnesium; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Stress response; Transferase.
FT   CHAIN           1..740
FT                   /note="Ribosomal protein S6 kinase alpha-3"
FT                   /id="PRO_0000086203"
FT   DOMAIN          68..327
FT                   /note="Protein kinase 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          328..397
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   DOMAIN          422..679
FT                   /note="Protein kinase 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..38
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        193
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        539
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250"
FT   BINDING         74..82
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         100
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         428..436
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         451
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         227
FT                   /note="Phosphoserine; by PDPK1"
FT                   /evidence="ECO:0000250|UniProtKB:P18654, ECO:0000305"
FT   MOD_RES         365
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         369
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         375
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195"
FT   MOD_RES         386
FT                   /note="Phosphoserine; by autocatalysis and MAPKAPK2"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:24275569"
FT   MOD_RES         415
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         529
FT                   /note="Phosphotyrosine; by FGFR3"
FT                   /evidence="ECO:0000250|UniProtKB:P18654"
FT   MOD_RES         556
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         715
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   VARIANT         38
FT                   /note="I -> S (in dbSNP:rs56218010)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:9837815"
FT                   /id="VAR_006188"
FT   VARIANT         75
FT                   /note="G -> V (in CLS; dbSNP:rs122454124)"
FT                   /evidence="ECO:0000269|PubMed:8955270"
FT                   /id="VAR_006189"
FT   VARIANT         82
FT                   /note="V -> F (in CLS; dbSNP:rs122454126)"
FT                   /evidence="ECO:0000269|PubMed:9837815"
FT                   /id="VAR_006190"
FT   VARIANT         114
FT                   /note="R -> W (in CLS; dbSNP:rs122454127)"
FT                   /evidence="ECO:0000269|PubMed:10094187"
FT                   /id="VAR_006191"
FT   VARIANT         115
FT                   /note="T -> S (in XLID19; dbSNP:rs387906703)"
FT                   /evidence="ECO:0000269|PubMed:17100996"
FT                   /id="VAR_065892"
FT   VARIANT         127
FT                   /note="H -> Q (in CLS)"
FT                   /evidence="ECO:0000269|PubMed:9837815"
FT                   /id="VAR_006192"
FT   VARIANT         152
FT                   /note="Missing (in XLID19; dbSNP:rs398122813)"
FT                   /evidence="ECO:0000269|PubMed:17100996"
FT                   /id="VAR_065893"
FT   VARIANT         154
FT                   /note="D -> Y (in CLS)"
FT                   /evidence="ECO:0000269|PubMed:9837815"
FT                   /id="VAR_006193"
FT   VARIANT         189
FT                   /note="I -> K (in CLS; dbSNP:rs122454130)"
FT                   /evidence="ECO:0000269|PubMed:10528858"
FT                   /id="VAR_065894"
FT   VARIANT         202
FT                   /note="Missing (in XLID19)"
FT                   /evidence="ECO:0000269|PubMed:17100996"
FT                   /id="VAR_065895"
FT   VARIANT         225
FT                   /note="A -> V (in CLS; dbSNP:rs879027948)"
FT                   /evidence="ECO:0000269|PubMed:9837815"
FT                   /id="VAR_006194"
FT   VARIANT         227
FT                   /note="S -> A (in CLS; dbSNP:rs122454125)"
FT                   /evidence="ECO:0000269|PubMed:8955270"
FT                   /id="VAR_006195"
FT   VARIANT         268
FT                   /note="F -> S (in CLS; dbSNP:rs122454131)"
FT                   /evidence="ECO:0000269|PubMed:14986828"
FT                   /id="VAR_065896"
FT   VARIANT         383
FT                   /note="R -> W (in XLID19; kinase activity is decreased but
FT                   not abolished; dbSNP:rs122454129)"
FT                   /evidence="ECO:0000269|PubMed:10319851"
FT                   /id="VAR_065897"
FT   VARIANT         416
FT                   /note="I -> V (in a breast cancer sample; somatic mutation;
FT                   dbSNP:rs148050184)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035627"
FT   VARIANT         431
FT                   /note="G -> D (in CLS)"
FT                   /evidence="ECO:0000269|PubMed:9837815"
FT                   /id="VAR_006196"
FT   VARIANT         477
FT                   /note="Missing (in CLS)"
FT                   /evidence="ECO:0000269|PubMed:15214012"
FT                   /id="VAR_065898"
FT   VARIANT         483
FT                   /note="Y -> C (in a gastric adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs1271090915)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040629"
FT   VARIANT         608
FT                   /note="L -> F (in a glioblastoma multiforme sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040630"
FT   VARIANT         723
FT                   /note="R -> C (in dbSNP:rs35026425)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040631"
FT   VARIANT         729
FT                   /note="R -> Q (in CLS; dbSNP:rs28935171)"
FT                   /evidence="ECO:0000269|PubMed:10094187"
FT                   /id="VAR_006197"
FT   CONFLICT        89
FT                   /note="S -> L (in Ref. 5; AAH96303)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        410
FT                   /note="Missing (in Ref. 3; BAD92170)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        424
FT                   /note="V -> L (in Ref. 6; AAC82495)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        480
FT                   /note="K -> N (in Ref. 6; AAC82495)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        494
FT                   /note="Missing (in Ref. 6; AAC82495)"
FT                   /evidence="ECO:0000305"
FT   HELIX           50..54
FT                   /evidence="ECO:0007829|PDB:5D9L"
FT   HELIX           65..67
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   STRAND          68..76
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   STRAND          78..87
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   TURN            91..94
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   STRAND          96..104
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   TURN            105..107
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   HELIX           109..124
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   STRAND          133..139
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   STRAND          142..148
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   STRAND          152..154
FT                   /evidence="ECO:0007829|PDB:5D9K"
FT   HELIX           155..162
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   HELIX           167..186
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   STRAND          189..192
FT                   /evidence="ECO:0007829|PDB:5D9L"
FT   HELIX           196..198
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   STRAND          199..201
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   STRAND          203..205
FT                   /evidence="ECO:0007829|PDB:4NUS"
FT   STRAND          207..209
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   STRAND          214..216
FT                   /evidence="ECO:0007829|PDB:5D9L"
FT   HELIX           217..223
FT                   /evidence="ECO:0007829|PDB:4NUS"
FT   TURN            224..226
FT                   /evidence="ECO:0007829|PDB:4NUS"
FT   HELIX           232..234
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   HELIX           237..240
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   HELIX           249..263
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   HELIX           273..282
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   HELIX           293..302
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   STRAND          304..306
FT                   /evidence="ECO:0007829|PDB:7OPO"
FT   HELIX           307..309
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   TURN            315..318
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   HELIX           319..322
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   HELIX           325..327
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   HELIX           332..336
FT                   /evidence="ECO:0007829|PDB:4NW6"
FT   HELIX           351..353
FT                   /evidence="ECO:0007829|PDB:5D9L"
FT   STRAND          409..411
FT                   /evidence="ECO:0007829|PDB:4JG7"
FT   HELIX           412..414
FT                   /evidence="ECO:0007829|PDB:4D9U"
FT   TURN            419..421
FT                   /evidence="ECO:0007829|PDB:4D9T"
FT   STRAND          422..430
FT                   /evidence="ECO:0007829|PDB:4D9T"
FT   STRAND          432..441
FT                   /evidence="ECO:0007829|PDB:4D9T"
FT   TURN            442..445
FT                   /evidence="ECO:0007829|PDB:4D9T"
FT   STRAND          446..454
FT                   /evidence="ECO:0007829|PDB:4D9T"
FT   TURN            455..457
FT                   /evidence="ECO:0007829|PDB:4D9T"
FT   HELIX           461..470
FT                   /evidence="ECO:0007829|PDB:4D9T"
FT   STRAND          479..484
FT                   /evidence="ECO:0007829|PDB:4D9T"
FT   STRAND          486..494
FT                   /evidence="ECO:0007829|PDB:4D9T"
FT   HELIX           501..506
FT                   /evidence="ECO:0007829|PDB:4D9T"
FT   HELIX           513..532
FT                   /evidence="ECO:0007829|PDB:4D9T"
FT   HELIX           542..544
FT                   /evidence="ECO:0007829|PDB:4D9T"
FT   STRAND          545..551
FT                   /evidence="ECO:0007829|PDB:4D9T"
FT   HELIX           554..556
FT                   /evidence="ECO:0007829|PDB:4D9T"
FT   STRAND          557..559
FT                   /evidence="ECO:0007829|PDB:4D9T"
FT   STRAND          571..573
FT                   /evidence="ECO:0007829|PDB:4JG8"
FT   HELIX           587..613
FT                   /evidence="ECO:0007829|PDB:4D9T"
FT   HELIX           626..635
FT                   /evidence="ECO:0007829|PDB:4D9T"
FT   HELIX           643..645
FT                   /evidence="ECO:0007829|PDB:4D9U"
FT   STRAND          646..648
FT                   /evidence="ECO:0007829|PDB:4JG6"
FT   HELIX           650..659
FT                   /evidence="ECO:0007829|PDB:4D9T"
FT   TURN            664..666
FT                   /evidence="ECO:0007829|PDB:4D9T"
FT   HELIX           670..673
FT                   /evidence="ECO:0007829|PDB:4D9T"
FT   HELIX           677..680
FT                   /evidence="ECO:0007829|PDB:4D9T"
FT   HELIX           682..684
FT                   /evidence="ECO:0007829|PDB:4D9T"
FT   HELIX           696..710
FT                   /evidence="ECO:0007829|PDB:4D9T"
FT   HELIX           711..713
FT                   /evidence="ECO:0007829|PDB:4JG8"
SQ   SEQUENCE   740 AA;  83736 MW;  486AE8357CEAB6C8 CRC64;
     MPLAQLADPW QKMAVESPSD SAENGQQIMD EPMGEEEINP QTEEVSIKEI AITHHVKEGH
     EKADPSQFEL LKVLGQGSFG KVFLVKKISG SDARQLYAMK VLKKATLKVR DRVRTKMERD
     ILVEVNHPFI VKLHYAFQTE GKLYLILDFL RGGDLFTRLS KEVMFTEEDV KFYLAELALA
     LDHLHSLGII YRDLKPENIL LDEEGHIKLT DFGLSKESID HEKKAYSFCG TVEYMAPEVV
     NRRGHTQSAD WWSFGVLMFE MLTGTLPFQG KDRKETMTMI LKAKLGMPQF LSPEAQSLLR
     MLFKRNPANR LGAGPDGVEE IKRHSFFSTI DWNKLYRREI HPPFKPATGR PEDTFYFDPE
     FTAKTPKDSP GIPPSANAHQ LFRGFSFVAI TSDDESQAMQ TVGVHSIVQQ LHRNSIQFTD
     GYEVKEDIGV GSYSVCKRCI HKATNMEFAV KIIDKSKRDP TEEIEILLRY GQHPNIITLK
     DVYDDGKYVY VVTELMKGGE LLDKILRQKF FSEREASAVL FTITKTVEYL HAQGVVHRDL
     KPSNILYVDE SGNPESIRIC DFGFAKQLRA ENGLLMTPCY TANFVAPEVL KRQGYDAACD
     IWSLGVLLYT MLTGYTPFAN GPDDTPEEIL ARIGSGKFSL SGGYWNSVSD TAKDLVSKML
     HVDPHQRLTA ALVLRHPWIV HWDQLPQYQL NRQDAPHLVK GAMAATYSAL NRNQSPVLEP
     VGRSTLAQRR GIKKITSTAL
//
